课题基金 / 基金详情

The Role of Complement Component C1Q in Tuberculosis and Diabetes Co-morbidity

The Role of Complement Component C1Q in Tuberculosis and Diabetes Co-morbidity
补体成分 C1Q 在结核病和糖尿病合并症中的作用
批准号:
MR/P017568/1
负责人:
Jacqueline Cliff
金额:
$44.93万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
People with type 2 diabetes mellitus (T2DM) have a three-fold enhanced risk of developing tuberculosis (TB) following infection than the general population. As the global burden of T2DM is rapidly growing, and increasingly overlapping with the TB epidemic particularly in low and middle income countries, there is an urgent need to develop new intervention strategies. The underlying causal mechanism linking the two diseases is unknown.The Complement system is part of the immune system which enhances the actions of immune cells and antibodies, enabling better killing and clearance of pathogens. The role of Complement in TB has not been fully investigated. Complement consists of several protein components, which can exert their effect on downstream components in a cascade pathway. The first component which is activated in the classical pathway is C1. Recently, it has been discovered that expression of C1q genes and proteins are upregulated in blood in TB patients, although its exact role is unclear. It may be acting to enhance killing of Mycobacterium tuberculosis bacilli by phagocytes, but it may also be allowing the bacilli to escape killing by down-regulating the killing ability of the phagocytes, as C1q is known to carry out a regulatory role in other diseases. C1q activity has also been implicated in T2DM, in which free circulating concentrations of C1q are elevated.In this project, we will ask whether C1q acts as a mechanistic link between TB and T2DM, such that elevated free C1q in T2DM patients predisposes them to develop TB disease. Further, we will investigate how C1q might act, by investigating its effects on macrophages, which are the main cell type infected by M. tuberculosis. Together, the studies will reveal whether C1q is an important regulator of TB disease development, as part of a common pathway linking TB disease susceptibility with T2DM pathogenesis.Additionally, the project will serve as a platform for enhancing scientific links between the London School of Hygiene & Tropical Medicine and Padjadjaran University, and facilitate capacity development particularly in cellular and molecular immunological techniques in the Indonesian laboratory.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ebiom.2022.104173
发表时间: 2022-08
期刊: EBIOMEDICINE
影响因子: 11.1
作者: [van Doorn, Cassandra L. R., Eckold, Clare, Ronacher, Katharina, Ruslami, Rovina, van Veen, Suzanne, Lee, Ji-Sook, Kumar, Vinod, Kerry-Barnard, Sarah, Malherbe, Stephanus T., Kleynhans, Leanie, Stanley, Kim, Hill, Philip C., Joosten, Simone A., van Crevel, Reinout, Wijmenga, Cisca, Critchley, Julia A., Walzl, Gerhard, Alisjahbana, Bachti, Haks, Marielle C., Dockrell, Hazel M., Ottenhoff, Tom H. M., Vianello, Eleonora, Cliff, Jacqueline M.]
通讯作者: Cliff, Jacqueline M.
DOI: 10.1093/cid/ciaa751
发表时间: 2021-01-23
期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子: --
作者: [Eckold C, Kumar V, Weiner J, Alisjahbana B, Riza AL, Ronacher K, Coronel J, Kerry-Barnard S, Malherbe ST, Kleynhans L, Stanley K, Ruslami R, Ioana M, Ugarte-Gil C, Walzl G, van Crevel R, Wijmenga C, Critchley JA, Dockrell HM, Cliff JM, TANDEM consortium]
通讯作者: TANDEM consortium
Impaired resolution of blood transcriptomes through tuberculosis treatment with diabetes comorbidity
合并糖尿病合并症的结核病治疗导致血液转录组分辨率受损
DOI: 10.1101/2022.02.07.22269422
发表时间: 2022
期刊:
影响因子: --
作者: [Eckold C]
通讯作者: Eckold C
DOI: 10.1002/ctm2.1375
发表时间: 2023-09
期刊: Clinical and translational medicine
影响因子: 10.6
作者: []
通讯作者:
6
    国内基金
    海外基金
    Complement C6蛋白抑制DNA损伤修复增敏甲状腺乳头状癌放射性碘治疗的作用及其机制
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      刘宇佳
    • 依托单位: